4d Molecular Therapeutics Stock News

4D Molecular Therapeutics, Inc. (FDMT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest furth

EMERYVILLE, Calif., Sept. 20, 2022 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics, Inc. (Nasdaq: FDMT), a clinical-stage biotherapeutics company harnessing the power of directed evolution for targeted

4D Molecular Therapeutics, Inc. (FDMT) delivered earnings and revenue surprises of -11.54% and 94.60%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for t

EMERYVILLE, Calif., June 02, 2022 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics, Inc. (Nasdaq: FDMT), a clinical-stage biotherapeutics company harnessing the power of directed evolution for targeted g

4D Molecular Therapeutics, Inc. (FDMT) delivered earnings and revenue surprises of -12.33% and 39.05%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for

4D Molecular Therapeutics, Inc. (FDMT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

EMERYVILLE, Calif., Feb. 11, 2022 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics, Inc. (Nasdaq: FDMT), a clinical-stage gene therapy company harnessing the power of directed evolution for targeted gene therapies, announced that management will participate in the 11 th Annual SVB Leerink Global Healthcare Conference on Wednesday, February 16 th . Details of the fireside chat are as follows:

EMERYVILLE, Calif., Feb. 11, 2022 (GLOBE NEWSWIRE) --  4D Molecular Therapeutics, Inc. (Nasdaq: FDMT), a clinical-stage gene therapy company harnessing the power of directed evolution for targeted ge

4D Molecular Therapeutics Inc (NASDAQ: FDMT ) has … Full story available on Benzinga.com

4D Molecular Therapeutics (FDMT) reported updated interim data from the ongoing phase 1/2 trial of 4D-310 in patients with Fabry disease.Following 4D-310 infusion, mean serum AGA

The U.S. IPO market was red-hot in 2021. The total number of traditional U.S. IPOs hit its highest level since the dot-com boom in the late 1990s, while total IPO deal value reached record levels la

4D Molecular Therapeutics Inc (FDMT) shares closed today at 1.0% above its 52 week low of $18.57, giving the company a market cap of $602M. The stock is currently down 14.5% year-to-date, down 57.6% over the past 12 months, and down 53.7% over the past five years. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 fell 1.9%. Trading Activity Trading volume this week was 56.1% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.1. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 811.1% The company's stock price performance over the past 12 months lags the peer average by 91.5% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

4D Molecular Therapeutics (FDMT) said the the first patient was dosed in a phase 1/2 trial of its gene therpay 4D-150 for neovascular age-related macular degeneration (wet AMD), a type

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) was the target of a significant decrease in short interest in November. As of November 30th, there was short interest totalling 880,000 shares, a decrease of 25.4% from the November 15th total of 1,180,000 shares. Based on an average trading volume of 259,800 shares, the short-interest ratio is presently 3.4 []